Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Vertex Pharmaceuticals Inc

NASDAQ: VRTX · Life Sciences · 5 alerts · CIK 875320

Share price
$537.79Close, Nov 16
Market cap
$136B
Shares outstanding
253.54MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Vertex Pharmaceuticals Inc filings on SEC EDGAR ↗

4:37 PM ET Form 4
Insider Selling

Vertex Pharmaceuticals EVP, Co & Fo Charles F. Wagner Jr. Sells $8.37M of Stock

Charles F. Wagner Jr., EVP, Co & Fo, sold 15,286 shares of Vertex Pharmaceuticals Inc at $547.87 a share, worth $8.37M in total on Nov 12, 2026. Shares held after the trade: 31,764 (-32.5%).

Value
$8.37M
Shares
15,286
Price
$547.87
Role
EVP, Co & Fo
Holding change
-32.5%
Trade date
Nov 12, 2026
4:21 PM ET Form 4
Insider Selling

Vertex Pharmaceuticals CEO & President Reshma Kewalramani Sells $6.31M of Stock

Reshma Kewalramani, CEO & President, sold 11,866 shares of Vertex Pharmaceuticals Inc at $531.53 a share, worth $6.31M in total on Nov 6, 2026. Shares held after the trade: 86,471 (-12.1%).

Value
$6.31M
Shares
11,866
Price
$531.53
Role
CEO & President
Holding change
-12.1%
Trade date
Nov 6, 2026
4:05 PM ET 10-Q
Financial Results

Vertex Pharmaceuticals Q3 2026 Results: Net Income $654M, Down 39.6% YoY

Vertex Pharmaceuticals reported total revenues of $3.44 billion for the third quarter of 2026, a 12% increase compared to the same period in 2025. Net income for the quarter was $653.6 million, down from $1.08 billion in the prior year, primarily driven by significantly higher operating expenses and a $9.06 billion acquisition of Crinetics Pharmaceuticals.

Key figure
Net income $654M · -39.6% YoY
4:06 PM ET 8-K
Financial Results

Vertex Pharmaceuticals Financial Results

Vertex Pharmaceuticals reported Q3 2026 revenue of $3.44 billion, a 12% increase year-over-year, driven by strong demand for its cystic fibrosis therapies and new product launches. The company raised its full-year 2026 revenue guidance to a range of $13.15 billion to $13.25 billion. During the quarter, Vertex also completed the $9 billion acquisition of Crinetics Pharmaceuticals and secured a $4.5 billion term loan.

“Vertex delivered excellent third quarter results marked by strong revenue growth across the increasingly diversified portfolio, continued advancement of the R&D pipeline, and the successful close of the Crinetics Pharmaceuticals acquisition.”

Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex

“With the potential povetacicept approval in IgAN coming later this month, we are well positioned to establish nephrology as our fifth commercial franchise and expand the reach of our transformative medicines to even more patients.”

Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex
4:10 PM ET 8-K
Leadership Change

Vertex Pharmaceuticals Leadership Change

Vertex Pharmaceuticals appointed Daniel Brennan to its Board of Directors, effective October 20, 2026, increasing the board size to eleven members. Mr. Brennan, the former CFO of Boston Scientific, will also serve on the Audit and Finance Committee and received an initial $400,000 restricted stock unit award.

Counterparty
Daniel Brennan

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.